Literature DB >> 22859849

Multiplicities in cancer research: ubiquitous and necessary evils.

Donald Berry1.   

Abstract

Scientific inquiry involves observations and measurements, some of which are planned and some of which are not. The most interesting or unusual observations might be regarded as discoveries and therefore particularly worthy of publication. However, the observational process is fraught with inferential land mines, especially if the discoveries are serendipitous. Multiple observations increase the probability of false-positive conclusions and have led to many false and otherwise misleading publications. Statisticians recommend adjustments to final inferences with the goal of reducing the rate of false positives, a strategy that increases the rate of false negatives. Some scientists object to making such adjustments, arguing that it should not be more difficult to determine the validity of a discovery simply because other observations were made. Which tack is right? How does one decide that any particular scientific discovery is real? Unfortunately, there is no panacea, no one-size-fits-all approach. The goal of this commentary is to elucidate the issues and provide recommendations for conducting and reporting results of empirical studies, with emphasis on the problems of multiple comparisons and other types of multiplicities, including what I call "silent multiplicities." Because of the many observations, outcomes, subsets, treatments, etc, that are typically made or addressed in epidemiology and biomarker research, these recommendations may be particularly relevant for such studies. However, the lessons apply quite generally. I consider both frequentist and Bayesian statistical approaches.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22859849      PMCID: PMC4614276          DOI: 10.1093/jnci/djs301

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  15 in total

1.  Drug development: Raise standards for preclinical cancer research.

Authors:  C Glenn Begley; Lee M Ellis
Journal:  Nature       Date:  2012-03-28       Impact factor: 49.962

2.  No adjustments are needed for multiple comparisons.

Authors:  K J Rothman
Journal:  Epidemiology       Date:  1990-01       Impact factor: 4.822

3.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

Authors:  Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark
Journal:  N Engl J Med       Date:  2004-12-10       Impact factor: 91.245

4.  HER2 and responsiveness of breast cancer to adjuvant chemotherapy.

Authors:  Kathleen I Pritchard; Lois E Shepherd; Frances P O'Malley; Irene L Andrulis; Dongsheng Tu; Vivien H Bramwell; Mark N Levine
Journal:  N Engl J Med       Date:  2006-05-18       Impact factor: 91.245

5.  HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15.

Authors:  S Paik; J Bryant; E Tan-Chiu; G Yothers; C Park; D L Wickerham; N Wolmark
Journal:  J Natl Cancer Inst       Date:  2000-12-20       Impact factor: 13.506

6.  Reporting recommendations for tumor marker prognostic studies (REMARK).

Authors:  Lisa M McShane; Douglas G Altman; Willi Sauerbrei; Sheila E Taube; Massimo Gion; Gary M Clark
Journal:  J Natl Cancer Inst       Date:  2005-08-17       Impact factor: 13.506

7.  erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.

Authors:  S Paik; J Bryant; C Park; B Fisher; E Tan-Chiu; D Hyams; E R Fisher; M E Lippman; D L Wickerham; N Wolmark
Journal:  J Natl Cancer Inst       Date:  1998-09-16       Impact factor: 13.506

8.  erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.

Authors:  A D Thor; D A Berry; D R Budman; H B Muss; T Kute; I C Henderson; M Barcos; C Cirrincione; S Edgerton; C Allred; L Norton; E T Liu
Journal:  J Natl Cancer Inst       Date:  1998-09-16       Impact factor: 13.506

9.  c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.

Authors:  H B Muss; A D Thor; D A Berry; T Kute; E T Liu; F Koerner; C T Cirrincione; D R Budman; W C Wood; M Barcos
Journal:  N Engl J Med       Date:  1994-05-05       Impact factor: 91.245

10.  Why most published research findings are false.

Authors:  John P A Ioannidis
Journal:  PLoS Med       Date:  2005-08-30       Impact factor: 11.613

View more
  10 in total

Review 1.  From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology.

Authors:  Kanwal Pratap Singh Raghav; Sminil Mahajan; James C Yao; Brian P Hobbs; Donald A Berry; Rebecca D Pentz; Alda Tam; Waun K Hong; Lee M Ellis; James Abbruzzese; Michael J Overman
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

2.  Assessment of vibration of effects due to model specification can demonstrate the instability of observational associations.

Authors:  Chirag J Patel; Belinda Burford; John P A Ioannidis
Journal:  J Clin Epidemiol       Date:  2015-06-06       Impact factor: 6.437

Review 3.  Biomarker development for axial spondyloarthritis.

Authors:  Matthew A Brown; Zhixiu Li; Kim-Anh Lê Cao
Journal:  Nat Rev Rheumatol       Date:  2020-06-30       Impact factor: 20.543

Review 4.  Biomarker validation: common data analysis concerns.

Authors:  Joe E Ensor
Journal:  Oncologist       Date:  2014-07-07

5.  Navigating the road ahead: addressing challenges for use of metabolomics in epidemiology studies.

Authors:  Majda Haznadar; Padma Maruvada; Eliza Mette; John Milner; Steven C Moore; Holly L Nicastro; Joshua N Sampson; L Joseph Su; Mukesh Verma; Krista A Zanetti
Journal:  Metabolomics       Date:  2014-04-01       Impact factor: 4.290

Review 6.  Prospects and pitfalls of personalizing therapies for sarcomas: from children, adolescents, and young adults to the elderly.

Authors:  Vivek Subbiah
Journal:  Curr Oncol Rep       Date:  2014-09       Impact factor: 5.075

Review 7.  Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures.

Authors:  Scott E Kern
Journal:  Cancer Res       Date:  2012-11-19       Impact factor: 12.701

8.  Vitamin E intake from natural sources and head and neck cancer risk: a pooled analysis in the International Head and Neck Cancer Epidemiology consortium.

Authors:  V Edefonti; M Hashibe; M Parpinel; M Ferraroni; F Turati; D Serraino; K Matsuo; A F Olshan; J P Zevallos; D M Winn; K Moysich; Z-F Zhang; H Morgenstern; F Levi; K Kelsey; M McClean; C Bosetti; S Schantz; G-P Yu; P Boffetta; S-C Chuang; Y-C A Lee; C La Vecchia; A Decarli
Journal:  Br J Cancer       Date:  2015-05-19       Impact factor: 7.640

9.  Predicting clinical trial results based on announcements of interim analyses.

Authors:  Kristine R Broglio; David N Stivers; Donald A Berry
Journal:  Trials       Date:  2014-03-07       Impact factor: 2.279

10.  The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context.

Authors:  Michael J Campbell; Denise Wolf; Rita A Mukhtar; Vickram Tandon; Christina Yau; Alfred Au; Frederick Baehner; Laura van't Veer; Donald Berry; Laura J Esserman
Journal:  PLoS One       Date:  2013-10-29       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.